New hope for Tough-to-Treat lung cancer: trial tests drug to boost Chemo's power
NCT ID NCT07155200
Summary
This study is testing whether adding a new drug called cirtuvivint to standard chemotherapy can better control small cell lung cancer that has returned after initial treatment. It will enroll about 42 adults whose cancer has progressed after prior platinum-based chemotherapy. The main goals are to find a safe dose for the combination and to see if it helps shrink tumors and delay cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.